Guardian Pharmacy Services, Inc. GRDN R2K
Company Overview
Guardian Pharmacy Services, Inc., a pharmacy service company, provides a suite of technology-enabled services to help residents of long-term health care facilities (LTCFs) in the United States. The company's individualized clinical, drug dispensing, and administration capabilities are used to serve the needs of residents in lower acuity LTCFs, such as assisted living facilities, behavioral health facilities, and group homes. Its Guardian Compass includes dashboards created using data from its data warehouse to help its local pharmacies plan, track, and optimize their business operations; GuardianShield Programs for LTCFs; Order Entry QA Analyzer, which utilizes real-time rules- engine technology to examine prescriptions and detect omissions and/or errors before they become a customer service problem; and Medication Spend Analyzer to break down the monthly drug spending for each of the LTCFs. Guardian Pharmacy Services, Inc. was founded in 2003 and is headquartered in Atlanta, Georgia.
Why Investors Should Care
Generates a return on equity of 26.9%, reflecting efficient use of shareholder capital.
Return on capital employed stands at 28.8%.
Revenue has grown at a 17.9% CAGR over the past five years.
Carries low leverage with a debt-to-equity ratio of 0.18.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Dec 2025 Revenue of $1.45B (+17.9% YoY); net profit $49.22M.
- Trailing 12 Months Year-on-year growth — revenue +2.2%, earnings +39.0%.
- 5-Year Trend Long-term compounding — revenue CAGR 17.9%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 17.93% |
| 1 Year: | 2.20% |
Compounded Profit Growth
| 5 Years: | - |
| 1 Year: | 39.00% |
Stock Price Performance
| 1 Year: | +94.56% |
| 6 Months: | +30.84% |
| 3 Months: | +0.46% |
| 1 Month: | -7.92% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)45.75 · Neutral
P/E of 47.23 is above the sector median of 25.41 — pricier than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Strong return on equity of 26.9%.
- Healthy ROCE of 28.8%.
- Compounding revenue at 17.9% over 5 years.
- Generates positive free cash flow.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | GRDN Guardian Pharmacy Services, Inc. R2K | 39.67 | 47.23 | $1.97B | 0.00% | 28.85% | 26.91% | 17.93% | - |
| 2 | LLY Eli Lilly and Company SPX | 1,152.54 | 41.02 | $1.03T | 0.61% | - | 107.46% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPX | 253.85 | 29.45 | $611.07B | 2.23% | 14.88% | 26.42% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPX | 244.78 | 119.40 | $432.48B | 3.04% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPX | 425.19 | 32.02 | $386.13B | 2.27% | 9.74% | 12.18% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPX | 120.78 | 34.02 | $298.31B | 2.86% | - | 18.94% | 5.64% | 10.01% |
| 7 | AZN AstraZeneca PLC NDX | 164.50 | 24.81 | $255.12B | 1.77% | 15.97% | 23.48% | 9.82% | 45.96% |
| 8 | TMO Thermo Fisher Scientific Inc. SPX | 534.07 | 29.33 | $198.47B | 0.40% | 8.14% | 13.52% | 8.81% | 12.95% |
| 9 | AMGN Amgen Inc. NDXSPX | 355.25 | 24.69 | $191.73B | 2.84% | 18.02% | 101.32% | 11.77% | 5.58% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 262.74M | 275.41M | 300.04M | 314.39M | 329.31M | 344.33M | 377.43M | 336.60M |
| Gross Profit | 52.19M | 55.10M | 61.29M | 60.88M | 64.35M | 68.15M | 74.72M | 76.31M |
| Operating Income | -6.33M | 7.93M | 17.00M | -104.61M | 13.01M | 12.58M | 16.35M | 17.68M |
| Net Income | - | - | 0 | -121.99M | 9.45M | 9.03M | 9.82M | 13.29M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2024 | Dec 2025 |
|---|---|---|
| Revenue | 1.23B | 1.45B |
| Gross Profit | 244.37M | 292.72M |
| Operating Income | -62.92M | 72.70M |
| Net Income | -110.05M | 49.22M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Total Assets | - | 320.81M | 412.66M |
| Total Equity | 59.86M | 149.98M | 217.92M |
| Cash & Equivalents | - | 4.66M | 65.62M |
| Long Term Debt | - | 0 | 0 |
| Total Liabilities | - | 170.83M | 194.73M |
| Current Liabilities | - | 144.12M | 160.70M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2024 | Dec 2025 |
|---|---|---|
| Operating Cash Flow | 57.96M | 100.25M |
| Investing Cash Flow | -30.41M | -32.23M |
| Financing Cash Flow | -23.64M | -7.07M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2024 | Dec 2025 |
|---|---|---|
| Gross Margin % | 19.9% | 20.2% |
| Operating Margin % | -5.1% | 5.0% |
| Net Margin % | -9.0% | 3.4% |
| ROE % | -73.4% | 22.6% |
| ROCE % | -35.6% | 28.9% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | FMR, LLC | 4.74% | 2.36M | $100.11M |
| 2 | Wellington Management Group, LLP | 3.55% | 1.77M | $74.89M |
| 3 | Blackrock Inc. | 3.53% | 1.76M | $74.52M |
| 4 | Woodline Partners LP | 2.62% | 1.31M | $55.43M |
| 5 | Brown Advisory Inc. | 2.53% | 1.26M | $53.43M |
| 6 | Vanguard Capital Management LLC | 2.46% | 1.23M | $52.00M |
| 7 | Valiant Capital Management, L.P. | 2.38% | 1.19M | $50.35M |
| 8 | Times Square Capital Management, LLC | 2.16% | 1.08M | $45.72M |
| 9 | T. Rowe Price Investment Management, Inc. | 2.07% | 1.03M | $43.63M |
| 10 | Boston Partners | 2.04% | 1.02M | $43.18M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for GRDN
The Technical Signals Behind (GRDN) That Institutions Follow - Stock Traders Daily
<a href="https://news.google.com/rss/articles/CBMi1gFBVV95cUxPWkV4RDJxTUVvN2ZaT05pRzY4TmtsTWdaaWExdkpWUXdmMDVxMWFNUk15TXFpTUhTVzNVdjhPWXFIeHQtM2ZGV3U4WlNfdzNJTXZMQnFjLUQ2VlJ4a3lFZG5nUndPWGg2VDZPQ3JQN1VKMDgyc1I2VWtmelRRTmQ2Z2ZMNXczOFhlNWY5an…
Guardian Pharmacy Services: Growth Is Durable, But Valuation Is Full (NYSE:GRDN) - Seeking Alpha
<a href="https://news.google.com/rss/articles/CBMiqwFBVV95cUxNSExPV091ZTh2b2Q3YmdILUpDQUIwd2xRZkk3aWt1OGVSOW1CbHp4T3JOR2k3RWZ2a1BoMElOdFhXcXhwZ0ZVM2NoM2VhQnJLdlByRWQ2em1JcUc3LVAzTG11U1NZbkEtRkNmemppUzR1OXdfaHFaX1ZaUVB1SEJ6ZEszc2l4R182TmdFaT…
GRDN Stock Price and Chart — NYSE:GRDN - TradingView
<a href="https://news.google.com/rss/articles/CBMiWkFVX3lxTE5tRnJYdklwMUtYSmN0T2RLc0JzUFVwTEJUVzdDaGRjSFRnWmxocTBVVjE0dnZ0V055SHJJWEZRR3RnaWxVUUFRNE9LY0hiX3R6SHlJYmlhalNBZw?oc=5" target="_blank">GRDN Stock Price and Chart — NYSE:GRDN</a>&nb…
Guardian Pharmacy (GRDN) Surges 8.8%: Is This an Indication of Further Gains? - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMinAFBVV95cUxNM0dxMEUyai1fWjFlV0pIa1M2d0xBbHVRc1IySVBDWFNhZ0xkd180MXZmT3VtUEFGS2wtLXMycUdhdWJhbmdSTnNBLXlNRzhQZE9MV2RQVVhiRWV1bUdhd2k0YUlCUTFXaEdKSmhVQVBESVZoN0RESU5oblVjZHl4elhvLW1DdHpadzFuaX…
Guardian Pharmacy adds a third Virginia LTC pharmacy in buyout - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiswFBVV95cUxNUmJ4MXZycm9sdlkxYmltcERZX1FCS2xHcGFvM0diN3dkeF8yWGo3Qi1Ca2RRLWc1VktweWdoaE5QYUswbDJyb2ZabUJjdV9ybVRQR2dyYjNIcmdvUUFmenV4YjJDY2o1WnkzRElBeUxxdTUwQ0hxTE9tSDJFWlRLYm0xQUdaLTEySXNDVV…
$GRDN stock is up 7% today. Here's what we see in our data. - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMinwFBVV95cUxQLWRzZEE2Q29ldDNieVJUOFpuTDhUZnpPUHg4bzZvWEpKeFZuUW1CYmpyZnhHd1p4WHBvRlpIMl8yUHZFWHRCZzFHU2I2QUR0TnVuTy1JODlFek8yV1B5UHI4THduNEN6LXc3X0RhbWo3QjdxZ3VxUE4wb0RtcFIxMUlUUGN2RjhrT1ZvaX…
GRDN — Frequently Asked Questions
What is the current share price of Guardian Pharmacy Services, Inc. (GRDN)?
As of 2026-07-14 21:23 PDT, Guardian Pharmacy Services, Inc. (GRDN) trades at $39.67 on NYSE. Its 52-week range is $19.88 to $43.40.
What is the market capitalisation of GRDN?
Guardian Pharmacy Services, Inc. (GRDN) has a market capitalisation of $1.97B on NYSE.
What is the P/E ratio of GRDN?
GRDN trades at a trailing price-to-earnings (P/E) ratio of 47.23. The industry average P/E is 25.41. Its price-to-book (P/B) ratio is 12.35.
What is the return on equity (ROE) of GRDN?
GRDN has a return on equity (ROE) of 26.91%. Its return on capital employed (ROCE) is 28.85%.
Is GRDN a good stock to buy?
This page provides a data-driven analysis of Guardian Pharmacy Services, Inc. (GRDN), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.